Wave Life Sciences Inc WVE

The pharma giant cut its partnership after a cancer drug disappointed in testing. Elsewhere, Teva and Samsung Bioepis expanded a partnership and space biotech Varda brought in $251 million.

Following meeting with FDA, Wave plans for a single, two-year registrational trial, with a one-year interim analysis for potential accelerated approval based on AATD biomarkers WVE-006 (RNA editing) has potential to offer the AATD community a new standard-of-care treatment to protect the liver and lung with a safe and convenient therapy CAMBRIDGE, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences, Inc. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad

Candidate selected by GSK utilizes Wave’s best-in-class SpiNA design siRNA and triggers a milestone payment to Wave; three additional collaboration programs advancing CAMBRIDGE, Mass., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences, Inc. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that as part of the companies’ research collaboration, GSK has selected a candidate for a hepatology

WVE-007 induces fat loss without muscle loss, with clinical data supporting 1-2x per year dosing; preclinical data demonstrate Wave’s INHBE GalNAc-siRNA in combination with GLP-1 doubled weight loss compared with GLP-1 alone Maintenance clinical trial evaluating WVE-007’s ability to curtail weight regain after incretin cessation on track to initiate 2H 2026 CAMBRIDGE, Mass., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused o

Dr. Vnuk brings substantial business and corporate development leadership experience from Sanofi, Blackstone, and Pfizer CAMBRIDGE, Mass., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced the appointment of Monika Vnuk, MD, as Chief Business Officer. Dr. Vnuk will join Wave’s executive team and lead business development, corporate de

CAMBRIDGE, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the Cantor 2026 Global Healthcare Conference in New York City on Thursday, September 10, 2026 at 9:45 a.m. ET. A live webcast of the present

Wave Life Sciences has lost nearly 70% of its value this year, yet its RNA platform spans obesity, rare liver disease, and genetic disorders in ways that could make it irresistible to the right buyer. The question is which pharma giant moves first.

Wave Life Sciences Ltd. reported second-quarter 2026 results with sales of US$2.27 million versus US$8.70 million a year earlier and a wider net loss of US$69.36 million, while first-half 2026 sales rose to US$40.52 million from US$17.87 million and net loss narrowed slightly to US$95.44 million. The company also completed court and shareholder approvals to shift its corporate domicile from Singapore to the United States, a corporate restructuring that could affect its regulatory framework,...

CAMBRIDGE, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- As previously announced, Wave Life Sciences Ltd. (NASDAQ: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health (“Wave” or “Wave Life Sciences”), has obtained the requisite shareholder approvals required in connection with its proposed redomiciliation (“Redomiciliation”) to the United States by way of the implementation of a statutory procedure known as a scheme of arran

CAMBRIDGE, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that members of Wave’s management team are scheduled to participate in two upcoming investor conferences in August. BofA Securities 2026 SMID Cap Executive Insights EventDate: Tuesday, August 11, 2026 Details: Paul Bolno, MD, MBA, President and CEO, will participate in

Moby summary of Wave Life Sciences Ltd.'s Q2 2026 earnings call

WAVE Life Sciences reports robust data for obesity candidate WVE-007 and AATD therapy WVE-006, while navigating a wider net loss and declining revenue.

Wave Life Sciences (WVE) delivered earnings and revenue surprises of -9.68% and -73.48%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?